IN2015DN03229A - - Google Patents
Info
- Publication number
- IN2015DN03229A IN2015DN03229A IN3229DEN2015A IN2015DN03229A IN 2015DN03229 A IN2015DN03229 A IN 2015DN03229A IN 3229DEN2015 A IN3229DEN2015 A IN 3229DEN2015A IN 2015DN03229 A IN2015DN03229 A IN 2015DN03229A
- Authority
- IN
- India
- Prior art keywords
- specific binding
- conjugated
- ibd
- molecule
- binding member
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2012/058574 WO2014055073A1 (en) | 2012-10-03 | 2012-10-03 | Antigens associated with inflammatory bowel disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03229A true IN2015DN03229A (enExample) | 2015-10-02 |
Family
ID=50435280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3229DEN2015 IN2015DN03229A (enExample) | 2012-10-03 | 2012-10-03 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9695232B2 (enExample) |
| EP (1) | EP2903629B1 (enExample) |
| JP (1) | JP6158933B2 (enExample) |
| KR (1) | KR102011549B1 (enExample) |
| CN (2) | CN104768563B (enExample) |
| AU (1) | AU2012391490B2 (enExample) |
| CA (1) | CA2886152C (enExample) |
| CO (1) | CO7380754A2 (enExample) |
| DK (1) | DK2903629T3 (enExample) |
| ES (1) | ES2743423T3 (enExample) |
| HU (1) | HUE044927T2 (enExample) |
| IL (1) | IL237856B (enExample) |
| IN (1) | IN2015DN03229A (enExample) |
| MX (1) | MX364535B (enExample) |
| PH (1) | PH12015500662B1 (enExample) |
| PL (1) | PL2903629T3 (enExample) |
| PT (1) | PT2903629T (enExample) |
| RU (1) | RU2612878C2 (enExample) |
| SG (1) | SG11201502404WA (enExample) |
| SI (1) | SI2903629T1 (enExample) |
| WO (1) | WO2014055073A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2209805B1 (en) | 2007-10-30 | 2017-09-06 | Philogen S.p.A. | An antigen associated with rheumatoid arthritis |
| EP2903629B1 (en) | 2012-10-03 | 2019-07-10 | Philogen S.p.A. | Antibody conjugate for use in treating inflammatory bowel disease |
| GB201507908D0 (en) | 2015-05-08 | 2015-06-24 | Philogen Spa | IL2 and TNF immunoconjugates |
| US20190309060A1 (en) | 2016-01-15 | 2019-10-10 | Philogen S.P.A. | Intestinal antigens for pharmacodelivery applications |
| EP3634999A1 (en) | 2017-06-07 | 2020-04-15 | Philogen S.p.A. | Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins |
| CN114072164A (zh) * | 2019-03-06 | 2022-02-18 | 德卡生物科学公司 | Il-10变体分子和治疗炎性疾病和肿瘤的方法 |
| WO2020249757A1 (en) | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
| CN116322785A (zh) | 2020-07-20 | 2023-06-23 | 德卡生物科学公司 | 包含il-10的双细胞因子融合蛋白 |
| EP4185615A1 (en) | 2020-07-22 | 2023-05-31 | Philogen S.p.A. | Treatment of pulmonary hypertension |
| US20250197485A1 (en) | 2022-03-17 | 2025-06-19 | Universitätsklinikum Jena | Anti-ED-A Antibodies for the Treatment of Pulmonary Hypertension |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE425839C (de) | 1923-08-09 | 1926-03-02 | Optische Anstalt C P Goerz Akt | Verfahren zur Erzeugung des Schleifdruckes und der Schleifrelativbewegung zwischen dem Gegenstande, dessen Oberflaeche durch Schleifen bearbeitet werden soll (Glas, Linse usw.), und der Schleifflaeche des umlaufenden Schleifwerkzeuges |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IT1217724B (it) | 1988-05-26 | 1990-03-30 | Ist Naz Ric Sul Cancro | Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori |
| US5420012A (en) | 1989-05-08 | 1995-05-30 | Locus Genex Oy | Method for the detection of reactive conditions |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| WO1992017604A1 (fr) | 1991-03-26 | 1992-10-15 | Otsuka Pharmaceutical Factory, Inc. | Anticorps monoclonal anti-eda |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| US5932214A (en) * | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5368854A (en) * | 1992-08-20 | 1994-11-29 | Schering Corporation | Use of IL-10 to treat inflammatory bowel disease |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5644033A (en) | 1992-12-22 | 1997-07-01 | Health Research, Inc. | Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment |
| US6054312A (en) | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
| DE69941267D1 (de) | 1998-12-10 | 2009-09-24 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
| US8623373B2 (en) | 2000-02-24 | 2014-01-07 | Philogen S.P.A. | Compositions and methods for treatment of angiogenesis in pathological lesions |
| CA2404919A1 (en) | 2000-04-06 | 2002-10-01 | Kyowa Hakko Kogyo Co. Ltd. | Diagnostic and therapeutic agents for rheumatoid arthritis |
| AU5867901A (en) | 2000-05-04 | 2001-11-12 | Philogen S.R.L. | Method for detecting tumors |
| US20020197700A1 (en) | 2000-09-07 | 2002-12-26 | Schering Ag | Receptor of the EDb-fibronectin domains |
| US6780594B2 (en) | 2000-09-25 | 2004-08-24 | Schering Aktiengesellschaft | Method for in vitro diagnosis of endometriosis |
| IT1317108B1 (it) | 2000-12-06 | 2003-05-26 | Philogen Srl | Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso. |
| US20020187100A1 (en) | 2000-12-21 | 2002-12-12 | David Rizzieri | Anti-tenascin monoclonal antibody therapy for lymphoma |
| EP1224943A1 (en) | 2001-01-19 | 2002-07-24 | Crucell Holland B.V. | Fibronectin as a tumor marker detected by phage antibodies |
| GB0209896D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| WO2004000216A2 (en) | 2002-06-21 | 2003-12-31 | Duke University | Anti-tenascin antibody fragments and minibodies for treatment of lymphoma |
| KR20050065587A (ko) | 2002-10-08 | 2005-06-29 | 이뮤노메딕스, 인코오포레이티드 | 항체 치료법 |
| CA2508831C (en) | 2002-12-13 | 2012-05-01 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
| CA2523452A1 (en) | 2003-04-22 | 2004-11-04 | A & G Pharmaceutical, Inc. | Cancer specific monoclonal antibodies |
| WO2005009366A2 (en) | 2003-07-24 | 2005-02-03 | Cornell Research Foundation, Inc. | Restoring vascular function |
| EP1660519B1 (en) | 2003-07-29 | 2014-05-14 | Immunomedics, Inc. | Conjugates comprising 2-[18F]fluoro-2-deoxy-D-glucose and a peptide molecule |
| US8048432B2 (en) | 2003-08-06 | 2011-11-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
| CA2552590A1 (en) | 2004-01-05 | 2005-07-21 | Emd Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
| US20060024722A1 (en) | 2004-07-30 | 2006-02-02 | Mark Fischer-Colbrie | Samples for detection of oncofetal fibronectin and uses thereof |
| US7785591B2 (en) | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
| SI1817345T1 (sl) | 2004-11-09 | 2009-10-31 | Philogen Spa | Protitelesa proti tenascinu-C |
| EP1831254B1 (en) | 2004-12-23 | 2012-06-06 | Molmed SpA | Conjugation product |
| MX2007013875A (es) | 2005-05-11 | 2008-01-28 | Philogen Spa | Proteinas de fusion del anticuerpo l19 contra fibronectina ed-b e interlucina 12. |
| AU2006262502A1 (en) | 2005-06-23 | 2007-01-04 | Emory Univerisity | Imaging agents |
| CN103145837A (zh) | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40结合蛋白 |
| JP2009535372A (ja) | 2006-05-03 | 2009-10-01 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 抗ｅｄｂフィブロネクチンドメイン抗体ｌ１９−ｓｉｐ及び抗−ｅｇｆｒ−抗体の組合せ |
| JP2009536170A (ja) | 2006-05-08 | 2009-10-08 | フィロジェン・エッセペア | 治療用の抗体標的指向サイトカイン |
| CA2682851C (en) | 2007-04-02 | 2017-01-17 | Philogen S.P.A. | A novel antigen associated with the neovasculature of tumour metastases |
| EA017995B1 (ru) | 2007-07-25 | 2013-04-30 | Филоджен С.П.А. | Антиген, связанный с вариантами рака легкого и лимфомами |
| EP2209805B1 (en) * | 2007-10-30 | 2017-09-06 | Philogen S.p.A. | An antigen associated with rheumatoid arthritis |
| EP2379116B1 (en) | 2009-01-07 | 2015-08-26 | Philogen S.p.A. | Antigens associated with endometriosis |
| WO2010078945A2 (en) | 2009-01-07 | 2010-07-15 | Philogen S.P.A. | Cancer treatment |
| US8679488B2 (en) | 2009-08-05 | 2014-03-25 | Philogen S.P.A. | Targeting of bone marrow neovasculature |
| EP3842074A1 (en) | 2010-09-29 | 2021-06-30 | Philogen S.p.A. | Protein-drug conjugates |
| ES2872964T3 (es) | 2011-07-27 | 2021-11-03 | Philogen Spa | Inmunoconjugado de IL-12 |
| EP2903629B1 (en) | 2012-10-03 | 2019-07-10 | Philogen S.p.A. | Antibody conjugate for use in treating inflammatory bowel disease |
| EP2988784A1 (en) | 2013-04-25 | 2016-03-02 | Philogen S.p.A. | Antibody-drug conjugates |
| JP2016519111A (ja) | 2013-04-26 | 2016-06-30 | フィロゲン エスピーエー | 細胞外マトリックス成分に対する抗体にコンジュゲートしたｉｌ４ |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2012
- 2012-10-03 EP EP12885969.1A patent/EP2903629B1/en active Active
- 2012-10-03 RU RU2015115399A patent/RU2612878C2/ru active
- 2012-10-03 US US14/431,745 patent/US9695232B2/en active Active
- 2012-10-03 PT PT12885969T patent/PT2903629T/pt unknown
- 2012-10-03 CN CN201280076034.8A patent/CN104768563B/zh active Active
- 2012-10-03 CN CN202010149309.2A patent/CN111329994A/zh active Pending
- 2012-10-03 WO PCT/US2012/058574 patent/WO2014055073A1/en not_active Ceased
- 2012-10-03 DK DK12885969.1T patent/DK2903629T3/da active
- 2012-10-03 SI SI201231649T patent/SI2903629T1/sl unknown
- 2012-10-03 ES ES12885969T patent/ES2743423T3/es active Active
- 2012-10-03 JP JP2015535617A patent/JP6158933B2/ja active Active
- 2012-10-03 HU HUE12885969 patent/HUE044927T2/hu unknown
- 2012-10-03 PL PL12885969T patent/PL2903629T3/pl unknown
- 2012-10-03 SG SG11201502404WA patent/SG11201502404WA/en unknown
- 2012-10-03 MX MX2015003908A patent/MX364535B/es active IP Right Grant
- 2012-10-03 CA CA2886152A patent/CA2886152C/en active Active
- 2012-10-03 AU AU2012391490A patent/AU2012391490B2/en active Active
- 2012-10-03 IN IN3229DEN2015 patent/IN2015DN03229A/en unknown
- 2012-10-03 KR KR1020157010676A patent/KR102011549B1/ko active Active
-
2015
- 2015-03-19 IL IL23785615A patent/IL237856B/en active IP Right Grant
- 2015-03-24 PH PH12015500662A patent/PH12015500662B1/en unknown
- 2015-03-26 CO CO15069808A patent/CO7380754A2/es unknown
-
2017
- 2017-06-01 US US15/611,213 patent/US10239939B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500662B1 (en) | Antigens associated with inflammatory bowel disease | |
| MX2019000225A (es) | Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades. | |
| EA201400579A1 (ru) | Антитела к il-36r | |
| EA032986B1 (ru) | Пирролобензодиазепины | |
| PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
| MA41031A (fr) | Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie | |
| WO2012047631A3 (en) | Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease | |
| EA201690310A1 (ru) | Антитела, связывающие cd27 человека, и их применение | |
| PH12013500810B1 (en) | Anti-il-23 antibodies | |
| MY171561A (en) | Conjugates for treating diseases caused by psma expressing cells | |
| MY163368A (en) | Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use | |
| NZ709059A (en) | Immunotherapy with binding agents | |
| PH12013500207A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| PH12013500337A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| PH12013500867A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| PH12012502523A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| MX356163B (es) | Anilinas sustituidas como antagonistas de ccr(4). | |
| MX365403B (es) | Peptidos y metodos para usarlos. | |
| FR2979346B1 (fr) | Nanocorps anti-vcam-1 | |
| IN2014DN06662A (enExample) | ||
| MX363385B (es) | Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias. | |
| CL2013001445A1 (es) | Compuestos derivados de difenilamina; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, tales como cancer. | |
| MY178558A (en) | Antigens associated with inflammatory bowel disease | |
| IN2015DN02818A (enExample) | ||
| MX2012012509A (es) | Tapentadol para usarse en el tratamiento del sindrome del intestino irritable. |